Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Interruption Arm Clear all
Completed Early Phase 1 Interventional Results available

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients

NCT05081583
View directory record Official record
Conditions
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Interventions
Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Not yet recruiting Not applicable Interventional

ACT-GEN (Adherence And Care Tracking In GENetic Cancer Syndromes)

NCT07565467
View directory record Official record
Conditions
ACT-GEN, Genetic Cancer Syndromes
Interventions
Standard of care, Interviews
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

NCT01977651
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Male only
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Enrolling by invitation Phase 4 Interventional

Nanozymes in Endodontics

NCT07518901
View directory record Official record
Conditions
Apical Periodontitis, Endodontic Disease, Root Canal Infection
Interventions
Nanozyme treatment, Control (Standard treatment)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Recurrent Low Back Pain: Linking Mechanism to Outcomes (RCT)

NCT01360359
View directory record Official record
Conditions
Low Back Pain
Interventions
Core Stabilization, Trunk Motion and Fitness
Other
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 11, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

NCT05205980
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Perturbation training
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
65 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Valdosta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed No phase listed Observational Results available

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

NCT02410811
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cardiac magnetic resonance imaging (CMR)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 11, 2026, 4:51 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Getting to Zero Among HHI MSM in the American South

NCT05075967
View directory record Official record
Conditions
HIV Infections
Interventions
Health Access Coalitions, Social Media, Peer Support, Promoting Human Autonomy Support & Empathy (PHASE)
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
15 Years and older · Male only
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Suspended Phase 1 Interventional

The DART DELIVER-02 Study

NCT07217379
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
MGD020, MGD014, Vorinostat, Temporary treatment interruption
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Not applicable Interventional Results available

Percutaneous Interruption of the Coracohumeral Ligament for the Treatment of Frozen Shoulder

NCT04549051
View directory record Official record
Conditions
Adhesive Capsulitis
Interventions
Tenex, Local anesthetic
Device · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia

NCT02415127
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Interferon γ-1b, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 25 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke

NCT04919161
View directory record Official record
Conditions
Stroke, Balance; Distorted
Interventions
Body weight support system control group, Body weight support system with balance perturbations
Device
Lead sponsor
Gaylord Hospital, Inc
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Following Pancreatic Surgery

NCT00660270
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancreatic Surgery, Radiation therapy, Cisplatin, 5-FU, Alpha-interferon, Gemcitabine
Procedure · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Acupuncture for Sleep Disruption in Cancer Survivors

NCT01162018
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Breast Cancer
Interventions
acupuncture, placebo
Procedure · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients

NCT01123655
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
APLA12, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 11, 2026, 4:51 PM EDT
Not yet recruiting Phase 1 Interventional

Botanical Therapy for Acute Viral Respiratory Infections

NCT07805447
View directory record Official record
Conditions
Acute Viral Respiratory Infection
Interventions
PurInf I Botanical Formulation, PurInf II Botanical Formulation, PurInf III Botanical Formulation, PurCo Botanical Formulation, PurPhl Botanical Formulation, PurClo Botanical Formulation
Drug
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

NCT04223804
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1
Interventions
ABBV-181, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Feasibility of Video Gaming Technology for Arm Recovery Early Post-stroke

NCT06691880
View directory record Official record
Conditions
Subacute Stroke, Acute Stroke
Interventions
MindPod Dolphin VGT, Bimanual Arm Trainer VGT
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409
View directory record Official record
Conditions
Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Interventions
MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

NCT00991224
View directory record Official record
Conditions
HIV Infections
Interventions
WT-gag-TCR modified T cells, α/6-gag-TCR modified T cells, STI or Drug Holiday
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

NCT00414635
View directory record Official record
Conditions
HIV Infections
Interventions
Intermitent Dosing
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 11, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

NCT04683679
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, Olaparib, Radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 11, 2026, 4:51 PM EDT